Sofosbuvir (Sovaldi)

Attachments

2014 Martin is credited with taking Sovaldi from "zero-to-blockbuster in a couple of months" with profits topping $10 billion for 2014.
2020 Rolling Stone - Big Pharma's Covid-19 Profiteers How the race to develop treatments and a vaccine will create a historic windfall for the industry - and everyone else will pay the price
That O'Day might come to such a conclusion was not outlandish. Gilead became infamous a few years ago for charging $84,000 per course of treatment for Sovaldi, a "groundbreaking" hepatitis-C drug.